ClinicalTrials.gg
CompletedNCT03489005Updated Dec 31, 2020

Effect of BIA 5 1058 on Cardiac Repolarization

A Phase 1 interventional study of BIA 5-1058 and Placebo Oral Tablet in Cardiovascular Disease, Pulmonary Arterial Hypertension and Heart Failure, sponsored by Bial - Portela C S.A.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-31.

Sponsored by Bial - Portela C S.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose is to evaluate the effect of single therapeutic (400 mg) and supratherapeutic (1200 mg) doses of BIA 5-1058 on the time-matched change from baseline in placebo-adjusted interval corrected (QT) for heart rate (HR)

Read the detailed description

This will be a Phase 1, randomized, double-blind, placebo-controlled and open-label, active controlled, 4 period, crossover study in healthy male and female subjects under fed conditions.

The study will be double blinded for BIA 5-1058 and placebo and open label for moxifloxacin. The central ECG laboratory and ECG readers will be blinded to study treatment sequence, timepoint, and subject. All subjects will receive each of the following 4 treatments:

  • 400 mg BIA 5 1058
  • 1200 mg BIA 5 1058
  • placebo
  • 400 mg moxifloxacin

Potential subjects will be screened to assess their eligibility to enter the study between 28 and 3 days prior to the first treatment administration. For each treatment period, subjects will be admitted into the Clinical Research Unit (CRU) on Day 2 and be confined to the CRU until Discharge on Day 4. Each subject will receive a single dose of study medication on Day 1 of each treatment period. There will be a washout of at least 10 days between doses, and subjects will return to the CRU for a Follow-up visit 14 ± 2 days after Period 4 Discharge. The total duration of study participation for each subject from Screening through Follow-up visit) is anticipated to be approximately 80 days.

The start of the study is defined as the date the first enrolled subject signs an Informed Consent Form (ICF). The point of enrollment occurs at the time of subject number allocation. The end of the study is defined as the date of the last subject's last assessment (scheduled or unscheduled).

02

Conditions studied

  • Cardiovascular Disease
  • Pulmonary Arterial Hypertension
  • Heart Failure

Keywords

  • BIA 5-1058
  • Pulmonary arterial hypertension
  • Heart failure
  • Cardiovascular Disease
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 939 are open to participants now.

This study's enrollment of 49 is below the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Bial - Portela C S.A. is the lead sponsor of 136 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18.0 and 28.0 kg/m2, inclusive.
  • In good health, determined by no findings from medical history, physical examination, vital sign measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [eg, Gilbert's syndrome] is acceptable) at Screening or Period 1 Check-in as assessed by the Investigator (or designee).
  • No clinically significant abnormalities in 12-lead rate, rhythm, or conduction at Screening or Period 1 Check-in.
  • Females will not be pregnant (negative pregnancy test at Screening and Period 1 Check in) or lactating, and females of and males will agree to use .
  • Able to comprehend and willing to sign an ICF before any study procedure and to abide by the study restrictions.

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).
  • Increased risk if dosed with moxifloxacin, according to the product label for moxifloxacin.
  • History of tendonitis or tendon rupture associated with treatment with quinolone antibiotics.
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed).
  • Subjects with >1.0 × the (ULN) and/or aspartate aminotransferase >1.0 × ULN and/or total >1.0 × ULN (isolated bilirubin >1.0 × ULN and ≤1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%), as confirmed by subsequent repeat assessment, at Screening or Period 1 Check-in.
  • Sustained supine systolic blood pressure >140 mmHg or \<90 mmHg or diastolic blood pressure >95 mmHg at Screening or baseline for Period 1 unless deemed not by the Investigator.
  • A resting HR \<45 bpm or >90 bpm.
  • An abnormal ECG indicating a second- or third-degree atrioventricular block, or one or more of the following: QRS interval >110 ms, \<300 ms or >450 ms, or PR interval >220 ms. Any rhythm other than sinus rhythm that is interpreted by the Investigator to be clinically significant.
  • History of additional risk factors for torsades de pointes (eg, heart failure, hypokalemia) or a family history of long QT syndrome or sudden death.
  • History of clinically significant alcoholism or drug/chemical abuse.
  • Alcohol consumption of >28 units per week for males and >21 units per week for females. One unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits.
  • Positive alcohol breath test result, positive urine cotinine test, or positive urine drug screen (confirmed by repeat) at Screening or Period 1 Check-in.
  • Positive hepatitis panel and/or positive test. Subjects whose results are compatible with prior immunization may be included at the discretion of the Investigator.
  • Participation in a clinical study involving administration of an drug (new chemical entity) in the past 90 days prior to the first dose.
  • Use or intend to use any medications/products known to alter QT/QTc within 14 days or 5 half-lives (whichever is longer) prior to the first dose, unless deemed acceptable by the Investigator (or designee).
  • Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to the first dose, unless deemed acceptable by the Investigator (or designee).
  • Use or intend to use any prescription medications/products including hormone replacement therapy and oral, implantable, transdermal, injectable, or intrauterine hormonal within 14 days prior to the first dose, unless deemed acceptable by the Investigator (or designee).
  • Use or intend to use any slow-release medications/products considered to still be active within 14 days prior to the first dose, unless deemed acceptable by the Investigator (or designee).
  • Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations within 7 days prior to the first dose, unless deemed acceptable by the Investigator (or designee).
  • Use of tobacco- or nicotine-containing products within 3 months prior to Screening.
  • Receipt of blood products within 2 months prior to Period 1 Check-in.
  • Donation of blood from 3 months prior to Screening, plasma from 2 weeks prior to Screening, or from 6 weeks prior to Screening.
  • Vegetarians, vegans, or other medical dietary restrictions.
  • Subjects who do not have suitable veins for multiple venipunctures/cannulation as assessed by the Investigator.
  • Have previously completed or withdrawn from this study or any other study investigating BIA 5 1058, and have previously received the investigational product.
  • Not able to reliably communicate with the Investigator or sub-Investigator.
  • Unlikely to cooperate with the requirements of the study.
  • Subjects who are study site employees or immediate family members of a study site or Sponsor employee.
  • Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
49 participants (actual)

Study arms

  • Other
    Treatment Period 1

    Interventions to be administered: Schema 1: 1. 400 mg BIA 5-1058 2. 1200 mg BIA 5-1058 3. Placebo 4. Moxifloxacin Schema 2: 1. 1200 mg BIA 5-1058 2. Placebo 3. 400 mg BIA 5-1058 4. Moxifloxacin

    Drug: BIA 5-1058 · Drug: Placebo Oral Tablet · Drug: Moxifloxacin 400 mg

  • Other
    Treatment Period 2

    Interventions to be administered: Schema 1 1. 1200 mg BIA 5-1058 2. Moxifloxacin 3. 400 mg BIA 5-1058 4. Placebo Schema 2: 1. Placebo 2. Moxifloxacin 3. 1200 mg BIA 5-1058 4. 400 mg BIA 5-1058

    Drug: BIA 5-1058 · Drug: Placebo Oral Tablet · Drug: Moxifloxacin 400 mg

  • Other
    Treatment Period 3

    Interventions to be administered: Schema 1 1. Placebo 2. 400 mg BIA 5-1058 3. Moxifloxacin 4. 1200 mg BIA 5-1058 Schema 2 1. 400 mg BIA 5-1058 2. 1200 mg BIA 5-1058 3. Moxifloxacin 4. Placebo

    Drug: BIA 5-1058 · Drug: Placebo Oral Tablet · Drug: Moxifloxacin 400 mg

  • Other
    Treatment Period 4

    Interventions to be administered: Schema 1 1. Moxifloxacin 2. Placebo 3. 1200 mg BIA 5-1058 4. 400 mg BIA 5-1058 Schema 2 1. Moxifloxacin 2. 400 mg BIA 5-1058 3. Placebo 4. 1200 mg BIA 5-1058

    Drug: BIA 5-1058 · Drug: Placebo Oral Tablet · Drug: Moxifloxacin 400 mg

Interventions

  • Subjects will receive BIA 5-1058 tablets (containing 100 mg) as single, oral doses 30 minutes after the start of a moderate mealas follows: * 400 mg BIA 5 1058, as 4 × 100 mg tablets and 8 placebo tablets * 1200 mg BIA 5 1058, as 12 × 100 mg tablets

    Also known as: Zamicastat

  • DrugPlacebo Oral Tablet

    Matching placebo tablets administered as follows: - placebo, as 12 × 0-mg tablets

  • Administered as follows: - 400 mg moxifloxacin, as 1 × 400-mg tablet

06

What researchers measure

Primary outcomes

  1. time-matched change from baseline in placebo-adjusted QT interval corrected for heart rate based on an individual correction method after BIA 5-1058 dosing.

    In each treatment period, continuous 12-lead digital ECG recording will be performed by Holter monitor for at least 24 hours prior to dose until approximately 24 hours postdose.

    Time frame: Day 1 at -1.25, -1, and -0.75 hours predose, Day -1 (baseline) at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, and 24 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, and 23 hours postdose.

Secondary outcomes

  1. QT interval corrected for heart rate based on the Fridericia correction (QTcF)

    In each treatment period, continuous 12-lead digital ECG recording will be performed by Holter monitor for at least 24 hours prior to dose until approximately 24 hours postdose.

    Time frame: Day 1 at -1.25, -1, and -0.75 hours predose, Day -1 (baseline) at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, and 24 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, and 23 hours postdose.

07

Study locations

1 site
  • Covance Clinical Research Unit Ltd.
    Leeds, LS29LH, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Oct 2018, 5 months.

Of 53 industry-sponsored phase 1 interventional studies under Cardiovascular Diseases, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 15. This study's 5 months is above that.

Counting every sponsor, half of 96 studies reached it within 15 months; a quarter within 3 and three quarters within 45.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2018
First posted
Apr 5, 2018
StartActual
Apr 9, 2018
Primary completionActual
Oct 5, 2018
CompletionActual
Oct 5, 2018
Last update
Dec 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03489005
Collaborators
Covance
Responsible party
Sponsor
First posted
Apr 5, 2018
Start date
Apr 9, 2018
Primary completion
Oct 5, 2018
Completion
Oct 5, 2018
Last update
Dec 31, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zamicastat

Start the discussion